Thomas G Stewart, Paulina A Rebolledo, Ahmad Mourad, Christopher J Lindsell, David R Boulware, Matthew W McCarthy, Florence Thicklin, Idania T Garcia Del Sol, Carolyn T Bramante, Leslie A Lenert, Stephen Lim, John C Williamson, Orlando Quintero Cardona, Jake Scott, Tiffany Schwasinger-Schmidt, Adit A Ginde, Mario Castro, Dushyantha Jayaweera, Mark Sulkowski, Nina Gentile, Kathleen McTigue, G Michael Felker, Allison DeLong, Rhonda Wilder, Russell L Rothman, Sean Collins, Sarah E Dunsmore, Stacey J Adam, George J Hanna, Elizabeth Shenkman, Adrian F Hernandez, Susanna Naggie
IMPORTANCE: The effect of higher-dose fluvoxamine in reducing symptom duration among outpatients with mild to moderate COVID-19 remains uncertain. OBJECTIVE: To assess the effectiveness of fluvoxamine, 100 mg twice daily, compared with placebo, for treating mild to moderate COVID-19. DESIGN, SETTING, AND PARTICIPANTS: The ACTIV-6 platform randomized clinical trial aims to evaluate repurposed medications for mild to moderate COVID-19. Between August 25, 2022, and January 20, 2023, a total of 1175 participants were enrolled at 103 US sites for evaluating fluvoxamine; participants were 30 years or older with confirmed SARS-CoV-2 infection and at least 2 acute COVID-19 symptoms for 7 days or less...
December 26, 2023: JAMA